Antiproliferative property and apoptotic effect of xanthorrhizol on MDA-MB-231 breast cancer cells

Anticancer Research

Volumn 28, Issue 6 A, 2008, Pages 3677-3689

  Yew, Hoong Cheah ^a,b   Nordin, Fariza Juliana ^a   Thiam, Tsui Tee ^b   Azimahtol, Hawariah Lope Pihie ^b   Abdullah, Noor Rain ^a   Ismail, Zakiah ^a  

^a INSTITUTE FOR MEDICAL RESEARCH   (Malaysia)

^b UNIVERSITI KEBANGSAAN MALAYSIA   (Malaysia)

Author keywords

Antiproliferative property; Apoptotic effect; MDA MB 231; Xanthorrhizol

Indexed keywords

ANTIBODY; CASPASE; CASPASE 3; CASPASE 6; CASPASE 8; CASPASE 9; CUCURMIN; CYTOCHROME C; FLUORESCEIN ISOTHIOCYANATE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; SESQUITERPENOID; SULFORHODAMINE B; TAMOXIFEN; UNCLASSIFIED DRUG; XANTHORRHIZOL;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL; CANCER GROWTH; CANCER INHIBITION; CANCER INVASION; CELL PROLIFERATION; CELL STRAIN; CELL STRAIN MDA MB 231; CONTROLLED STUDY; CYTOSOL; DRUG ACTIVITY; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME RELEASE; GROWTH INHIBITION; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE TEST; MEMBRANE DAMAGE; MEMBRANE POTENTIAL; MITOCHONDRIAL MEMBRANE; MITOCHONDRION; PRIORITY JOURNAL; WESTERN BLOTTING;

ANIMALS; APOPTOSIS; BISBENZIMIDAZOLE; BREAST NEOPLASMS; CASPASES; CATTLE; CELL GROWTH PROCESSES; CELL LINE; CELL LINE, TUMOR; CERCOPITHECUS AETHIOPS; CYTOCHROMES C; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME ACTIVATION; HUMANS; ISOENZYMES; PHENOLS; POLY(ADP-RIBOSE) POLYMERASES; STAINING AND LABELING; VERO CELLS;

EID: 58149148382     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (87)

1. Hentschel C, Eglau MC and Hahn EG: Curcuma xanthorrhiza (Java tumeric) in clinical use. Fortschr Med 114: 349-350, 1996.
2. Uehara S, Yasuda I, Takeya K and Itokawa H: Terpenoids and curcuminoids of the rhizome of Curcuma xanthorrhiza Roxb. Yakugaku Zasshi 112: 817-823, 1992.
3. Ibrahim J, Abu Said A, Nor Azah MN, Abdul Rashih A and Halijah I: Chemical composition of the rhizome oils of four Curcuma species from Malaysia. J Ess Oil Res 11: 719-723, 1999.
4. Hasnah MS and Lee LM: Analysis of the essential oils of two curcuma species. Malaysian J Anal Sci 8: 41-43, 2004.
5. Park JH, Kim JH, Park KK, Kim HO, Hwang JK and Chung WY: Chemopreventive effect of xanthorrhizol from Curcuma xanthorrhiza. J Korean Assoc Cancer Prev 8: 91-97, 2003.
6. Lim CS, Jin DQ, Mok H, Oh SJ, Lee JU, Hwang JK, Ha I and Han JS: Antioxidant and anti-inflammatory activities of xanthorrhizol in hippocampal neurons and primary cultured microglia. J Neurosci Res 82: 831-838, 2005.
7. Lee SK, Hong CH, Huh SK, Kim SS, Oh OJ, Min HY, Park KK, Chung WY and Hwang JK: Suppressive effect of natural sesquiterpenoids on inducible cyclooxygenase (COX-2) and nitric oxide synthase (iNOS) activity in mouse macrophage cells. J Environ Pathol Toxicol Oncol 21: 141-148, 2002
8. Kim SH, Hong KO. Hwang JK and Park KK: Xanthorrhizol has a potential to attenuate the high dose cisplatin-induced nephrotoxicity in mice. Food Chem Toxicol 43: 117-122, 2005.
9. Kim SH, Hong KO, Chung WY, Hwang JK and Park KK: Abrogation of cisplatin-induced hepatotoxicity in mice by xanthorrhizol is related to its effect on the regulation of gene transcription. Toxicol Appl Pharmacol 196: 346-355, 2004.
10. Hong KO, Chung WY, Hwang JK and Park KK: Phosphorylation of c-Jun N-terminal kinases (JNKs) is involved in the preventive effect of xanthorrhizol on cisplatin-induced hepatotoxicity. Arch Toxicol 79: 231-236, 2005.
11. Rukayadi Y and Hwang JK: In vitro antimycotic activity of xanthorrhizol isolated from Curcuma xanthorrhiza Roxb. against opportunistic filamentous fungi. Phytother Res 21: 434-438, 2007.
12. Hwang JK, Shim JS, Baek NI and Pyun YR: Xanthorrhizol: a potential antibacterial agent from Curcuma xanthorrhiza against Streptococcus mutans. Planta Med 66: 196-197, 2000.
13. Mata R, Martinez E, Bye R, Morales G, Singh MP, Janso JE, Maiese WM and Timmermann B: Biological and mechanistic activities of xanthorrhizol and 4-(1′, 5′-dimethylhex-4′-enyl)-2-methylphenol isolated from Iostephane heterophylla. J Nat Prod 64: 911-914, 2001.
14. Rukayadi Y and Hwang JK: Effect of coating the wells of a polystyrene microtiter plate with the xanthorrhizol on the biofilm formation of Streptococcus mutans. J Basic Microbiol 46: 410-415, 2006.
15. Itokawa H, Hirayama F, Funakoshi K and Takeya K: Studies on the antitumor bisabolane sesquiterpenoids isolated from Curcuma xanthorrhiza. Chem Pharm Bull 33: 3488-3492, 1985.
16. Chung WY, Park JH, Kim MJ, Kim HO, Hwang JK, Lee SK and Park KK: Xanthorrhizol inhibits 12-O-tetradecanoylphorbol-13-acetate-induced acute inflammation and two-stage mouse skin carcinogenesis by blocking the expression of ornithine decarboxylase, cyclooxygenase-2 and inducible nitric oxide synthase through mitogen-activated protein kinases and/or the nuclear factor-kappa B. Carcinogenesis 28: 1224-1231, 2007.
17. Choi MA, Kim SH, Chung WY, Hwang JK and Park KK: Xanthorrhizol, a natural sesquiterpenoid from Curcuma xanthorrhiza, has an anti-metatastic potential in experimental mouse lung metatastic model. Biochem Biophys Res Commun 326: 210-217, 2005.
18. Cheah YH, Azimahtol HLP and Abdullah NR: Xanthorrhizol exhibits antiproliferative activity on MCF-7 breast cancer cells via apoptosis induction. Anticancer Res 26: 4527-4534, 2006.
19. Ismail N, Pihie AHL and Nallapan M: Xanthorrhizol induces apoptosis via the up-regulation of bax and p53 in HeLa cells. Anticancer Res 25: 2221-2227, 2005.
20. Handayani T, Sakinah S, Nallapan M and Pihie AH: Regulation of p53-, Bcl-2- and caspase-dependent signaling pathway in xanthorrhizol-induced apoptosis of HepG2 hepatoma cells. Anticancer Res 27: 965-971, 2007.
21. Sheikh MS, Garcia M, Pujol P, Fontana JA and Rochefort H: Why are estrogen-receptor-negative breast cancers more aggresive than the estrogen-receptor-positive breast cancers? Invasion Metastasis 14: 329-336, 1995.
22. Balduyck M, Zerimech F, Gouyer V, Lemaire R, Hemon B, Grard G, Thiebaut C, Lemaire V, Dacquembronne E, Duhem T, Lebrun A, Dejonghe MJ and Huet G: Specific expression of matrix metalloproteinases 1, 3, 9, and 13 associated with invasiveness of breast cancer cells in vitro. Clin Exp Metastasis 18: 171-178, 2000.
23. Geisler S, Børresen-Dale AL, Johnsen H, Aas T, Geisler J, Akslen LA, Anker G and Lønning PE: TP53 gene mutations predict the response to neoadjuvant treatment with 5-fluorouracil and mitomycin in locally advanced breast cancer. Clin Cancer Res 9: 5582-5588, 2003.
24. Greenblatt MS, Bennett WP, Hollstein M and Harris CC: Mutations in the p53 tumor suppressor genes: clues to cancer etiology and molecular pathogenesis. Cancer Res 54: 4855-4878, 1994.
25. Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D, Warren JT, Bokesch H, Kenney S and Boyd MR: New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 82: 1107-1112, 1990.
26. Albuschat R, Lowe W, Weber M, Luger P and Jendrossek V: 4-Anilinoquinazolines with Lavendustin A subunit as inhibitors of epidermal growth factor receptor tyrosine kinase: syntheses, chemical and pharmacological properties. Eur J Med Chem 39: 1001-1011, 2004.
27. Vichai V and Kirtikara K: Sulforhodamine B colorimetric assay for cytotoxicity screening. Natl Cent Genet Eng Biotechnol 1: 1112-1116, 2006.
28. Lieberman MM, Patterson GML and Moore RE: In vitro bioassays for anticancer drug screening: effects of cell concentration and other assay parameters on growth inhibitory activity. Cancer Lett 173: 21-29, 2001.
29. Holbeck SL: Update on NCI in vitro drug screen utilities. Eur J Cancer 40: 785-793, 2004.
30. Rostom SAF: Synthesis and in vitro antitumor evaluation of some indeno (1, 2-c)-pyrazol(in)es substituted with sulfonamide, sulfonylurea(- thiourea) pharmacophores, and some derived thiazole ring systems. Bioorg Med Chem 14: 6475-6485, 2006.
31. Tee TT and Azimahtol HLP: Induction of apoptosis by Eurycoma longifolia Jack extracts. Anticancer Res 25: 2205-2214, 2005.
32. Shih SF, Wu YH, Hung CH, Yang HY and Lin JY: Abrin triggers cell death by inactivating a thiol-specific antioxidant protein. J Biol Chem 276: 21870-21877, 2001.
33. Ogawa Y, Kobayashi T, Nishioka A, Kariya S, Ohnishi T, Hamasato S, Seguchi H and Yoshida S: Reactive oxygen species-producing site in radiation and hydrogen peroxide-induced apoptosis of human peripheral T-cells: Involvement of lysosomal membrane destabilization. Int J Mol Med 13: 655-660, 2004.
34. Cheng AL, Hsu CH, Lin JK, Hsu MM, Ho YF, Shen TS, Ko JY, Lin JT, Lin BR, Ming-Shiang W, Yu HS, Jee SH, Chen GS, Chen TM, Chen CA, Lai MK, Pu YS, Pan MH, Wang YJ, Tsai CC and Hsieh CY: Phase 1 clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or premalignant lesions. Anticancer Res 21: 2895-2900, 2001.
35. Bemis DL, Katz AE and Buttyan R: Clinical trials of natural products as chemopreventive agents for prostate cancer. Expert Opin Investig Drugs 15: 1191-1200, 2006.
36. Hsu CH and Cheng AL: Clinical studies with curcumin. Adv Exp Med Biol 595: 471-480, 2007.
37. Ogawa Y, Nishioka A, Kobayashi T, Kariya S, Hamsato S, Saibara T, Nakayama K, Seguchi H and Yoshida S: Mitochondrial cytochrome c release in radiation-induced apoptosis of human peripheral T-cells. Int J Mol Med 10: 263-268, 2002.
38. Huang LY, Hu JD, Chen XJ, Zhu LF and Hu HL: Effects of emodin on the proliferation inhibition and apoptosis induction in HL-60 cells and the involvement of c-myc gene. Zhonghua Xue Ye Xue Za Zhi 26: 348-351, 2005.
39. Mann J: Natural Products in cancer chemotherapy: Past, present and future. Nat Rev Cancer 2: 143-148, 2002.
40. Treasure J: Herbal medicine and cancer: an introductory overview. Semin Oncol Nurs 21: 177-183, 2005.
41. Walsh V and Goodman J: Cancer chemotherapy, biodiversity, public and private property: The case of the anticancer drug Taxol. Soc Sci Med 49: 1215-1225, 1999.
42. Padron JM, Van Der Wilt CL, Smid K, Smitskamp-Wilms E, Backus HHJ, Pizao PE, Giaccone G and Peters GJ: The multilayered postconfluent cell culture as a model for drug screening. Crit Rev Oncol Hematol 36: 141-157, 2000.
43. Rennstam K, Jonsson G, Tanner M, Bendahl PO, Staaf J, Kapanen AI, Karhu R, Baldetorp B, Borg A and Isola J: Cytogenetic characterization and gene expression profiling of the trastuzumab-resistant breast cancer cell line JIMT-1. Cancer Genet Cytogenet 172: 95-106, 2007.
44. Horiatis D, Wang Q and Pinski J: A new screening system for proliferation-independent anti-cancer agents. Cancer Lett 210: 119-124, 2004.
45. Clemons M, Danson and Howell A: Tamoxifen ('Nolvadex'): A review. Cancer Treat Rev 28: 165-180, 2002.
46. Bradbury BD, Lash TL, Kaye JA and Jick SS: Tamoxifen-treated breast carcinoma patients and the risk of acute myocardial infarction and newly-diagnosed angina. Cancer 103: 1114-1121, 2005.
47. Geiger AM, Chen W and Bernstein L: Myocardial infarction risk and tamoxifen therapy for breast cancer. Br J Cancer 92: 1614-1620, 2005.
48. Ho CY, Kim CF, Leung KN, Fung KP, Tse TF, Chan H and Lau CB: Differential antitumor activity of Coriolus versicolor (Yunzhi) extract through p53- and/or Bcl-2-dependent apoptotic pathway in human breast cancer cells. Cancer Biol Ther 4: 638-644, 2005.
49. Gu Y and Leonard J: In vitro effects on proliferation, apoptosis and colony inhibition in ER-dependent and ER-independent human breast cancer cells by selected mushroom species. Oncol Rep 15: 417-423, 2006.
50. O' Connor PM, Jackman J, Bae I, Myers TG, Fan S, Mutoh M, Scudiero DA, Monks A, Sausville EA, Weinstein JN, Friend S, Jr AJF and Kohn KW: Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents. Cancer Res 57: 4285-4300, 1997.
51. Bando H, Toi M, Kitada K and Koike M: Genes commonly upregulated by hypoxia in human breast cancer cells MCF-7 and MDA-MB-231. Biomed Pharmacother 57: 333-340, 2003.
52. Bartsch JE, Staren ED and Appert HE: Matrix metalloproteinase expression in breast cancer. J Surg Res 110: 383-392, 2003.
53. Lewis JS, Meeke K, Osipo C, Ross EA, Kidawi N, Li T, Bell E, Chandel NS and Jordan VC: Intrinsic mechanism of estradiol-induced apoptosis in breast cancer cells resistant to estrogen deprivation. J Natl Cancer Inst 97: 1746-1759, 2005.
54. Choi B, Kim H, Lee K, Cho Y and Kong G: Clofilium, a potassium channel blocker, induces apoptosis of human promyelocytic leukaemia (HL-60) cells via Bcl-2 insensitive activation of caspase-3. Cancer Lett 147: 85-93, 1999.
55. Fleischer A, Ghadiri A, Dessauge F, Duhamel M, Rebollo MP, Alvarez-Flanco F and Rebollo A: Modulating apoptosis as a target for effective therapy. Mol Immunol 43: 1065-1079, 2006.
56. Liu Y, Bhalla K, Hill C and Priest DG: Evidence for involvement of tyrosine phosphorylation in taxol-induced apoptosis in a human ovarian tumor cell line. Biochem Pharmacol 48: 1265-1272, 1994.
57. Shrivastava A, Tiwari M, Sinha RA, Kumar A, Balapure AK, Bajpai VK, Sharma R, Mitra K, Tandon A and Godbole MM: Molecular iodine induces caspase-independent apoptosis in human breast carcinoma cells involving the mitochondria-mediated pathway. J Biol Chem 281: 19762-19771, 2006.
58. Bortner CD and Cidlowski JA: A necessary role for cell shrinkage in apoptosis. Biochem Pharmacol 56: 1549-1559, 1998.
59. Saraste A and Pulkki K: Morphologic and biochemical hallmarks of apoptosis. Cardiovasc Res 45: 528-537, 2000.
60. Kiechle FL and Zhang X: Apoptosis: Biochemical aspects and clinical complications. Clin Chim Acta 326: 27-45, 2002.
61. Kallio A, Zheng A, Dahllund J, Heiskanen K and Harkonen P: Role of mitochondria in tamoxifen-induced rapid death of MCF-7 breast cancer cells. Apoptosis 10: 1395-1410, 2005.
62. Gosslau A, Pabbaraja S, Knapp S and Chen KY: Trans- and cis- stilbene polyphenols induced rapid perinuclear mitochondrial clustering and p53-independent apoptosis in cancer cells but not normal cells. Eur J Pharmacol 587: 25-34, 2008.
63. Kuo P, Hsu Y, Chang C and Lin C: The mechanism of ellipticine-induced apoptosis and cell cycle arrest in human breast MCF-7 cancer cells. Cancer Lett 223: 293-301, 2005.
64. Satyan KS, Swamy N, Dizon DS, Singh R, Granai CO and Brard L: Phenethyl isothiocyanate (PEITC) inhibits growth of ovarian cancer cells by inducing apoptosis: Role of caspase and MAPK activation. Gynecol Oncol 103: 261-279, 2006.
65. Zhong X, Zhu Y, Lu Q, Zhang J, Ge Z and Zheng S: Silymarin causes caspases activation and apoptosis in K562 leukemia cells through inactivation of Akt pathway. Toxicol 227: 211-216, 2006.
66. Gonda K, Tsuchiya H, Sakabe T, Akechi Y, Ikeda R, Nishio R, Terabayashi K, Ishii K, Matsumi Y, Ashla AA, Okamoto H, Takubo K, Matsuoka S, Watanabe Y, Hoshikawa Y, Kurimaso A and Shiota G: Syntethic retinoid CD437 induces mitochondria-mediated apoptosis in hepatocellular carcinoma cells. Biochem Biophys Res Comm 370: 629-633, 2008.
67. Ozoren N and El-Deiry WS: Cell surface death receptor signalling in normal and cancer cells. Semin Cancer Biol 13: 135-147, 2003.
68. Sprick MR and Walczak H: The interplay between the Bcl-2 family and death receptor-mediated apoptosis. Biochim Biophys Acta 1644: 125-132, 2004.
69. Wang X, Yuan S, Wang J, Lin P, Liu G, Lu Y, Zhang J, Wang W and Wei Y: Anticancer activity of litchi fruit extract against human breast cancer in vitro and in vivo. Toxicol Appl Pharm 215: 168-178, 2006.
70. Cowling V and Downward J: Caspase-6 is the direct activator of caspase-8 in the cytochrome c-induced apoptosis pathway: absolute requirement for removal of caspase-6 prodomain. Cell Death and Differ 9: 1046-1056, 2002.
71. Ong RCY, Lei J, Lee RKY, Cheung JYN, Fung KP, Lin C, Ho HP, Yu B, Li M and Kong SK: Polyphillin D induces mitochondrial fragmentation and acts directly on the mitochondria to induce apoptosis in drug-resistant HEPG2 cells. Cancer Lett 261: 158-164, 2008.
72. Gogvadze V, Orrenius S and Zhivatovsky B: Mitochondria in cancer cells: what is so special about them? Trends Cell Biol 18: 165-173, 2008.
73. Kirsch DG, Doseff A, Chau BN, Lim DS, De Souza-Pinto NC, Hansford R, Kastan MB, Lazebnik YA and Hardwick JM: Caspase-3-dependent cleavage of Bcl-2 promotes release of cytochrome c. J Biol Chem 274: 21155-21161, 1999.
74. Slee EA, Harte MT, Kluck RM, Wolf BB, Casiano CA, Newmeyer DD, Wang HG, Reed JC, Nicholson DW, Alnemri ES, Green DR and Martin SJ: Ordering the cytochrome c-initiated caspase cascade: Hierarchical activation of caspase-2, -3, -6, -7, -8, and -10 in a caspase-9-dependent manner. J Cell Biol 144: 281-292, 1999.
75. Devarajan E, Sahin AA, Chen JS, Krishnamurthy RR, Aggarwal N, Brun AM, Sapino A, Zhang F, Sharma D, Yang XH, Tora AD and Mehta K: Down-regulation of caspase 3 in breast cancer: A possible mechanism for chemoresistance. Oncogene 21: 8843-8851, 2002.
76. Janicke RU, Sprengart ML, Wati MR and Porter AG: Caspase-3 is required for DNA fragmentation and morphological changes associated with apoptosis. J Biol Chem 273: 9357-9360, 1998.
77. Suyama E, Kawasaki H and Taira K: Identification of a caspase 3-independent role of pro-apoptotic factor Bak in TNF-α-induced apoptosis. FEBS Lett 528: 63-69, 2002.
78. Yang S, Zhou Q and Yang X: Caspase-3 status is a determinant of the differential responses to genistein between MDA-MB-231 and MCF-7 breast cancer cells. Biochim Biophys Acta 1773: 903-911, 2007.
79. Yelamos J, Schreiber V and Dantzer F: Towards specific functions of poly(ADP-ribose) polymerase-2. Trends Mol Med 14: 169-178, 2008.
80. Subhashini J, Mahipal SVK and Reddanna P: Anti-proliferative and apoptotic effects of celecoxib on human chronic myeloid leukemia in vitro. Cancer Lett 224: 31-43, 2005.
81. Racz I, Tory K, Gallyas FJ, Berente Z, Osz E, Jaszlits L, Bernath S, Sumegi B, Rabloczky G and Nagy PL: BGF-15 - a novel poly(ADP-ribose) polymerase inhibitor - protects against nephrotoxicity of cisplatin without compromising its antitumor activity. Biochem Pharmacol 63: 1099-1111, 2002.
82. Woodhouse BC and Dianov GL: Poly ADP-ribose polymerase-1: An international molecule of mystery. DNA Repair 7: 1077-1086, 2008.
83. Bouchard VJ, Rouleau M and Poirier GG: PARP-1, a determinant of cell survival in response to DNA damage. Exp Hematol 31: 446-454, 2003.
84. Alexandre S, Rast C, Nguyen-Ba G, Poirier GG and Vasseur P: PARP degradation in apoptotic Syrian hamster embryo (SHE) cells compared to HL60 cell line. Biochimie 82: 1115-1122, 2000.
85. Tee TT, Cheah YH and Hawariah LPA. F16, a fraction from Eurycoma longifolia Jack extract, induces apoptosis via a caspase-9- independent manner in MCF-7 Cells. Anticancer Res 27: 3425-3430, 2007.
86. Sabol SL, Li R, Lee TY and Abdul-Khalek R: Inhibition of apoptosis-associated DNA fragmentation activity in nonapoptotic cells: the role of DNA fragmentation factor-45 (DFF45/ICAD). Biochem Biophys Res Commun 253: 151-158, 1998.
87. Simbulan-Rosenthal CM, Rosenthal DS, Luo R and Smulson ME: Poly-(ADP-ribosyl)ation of p53 during apoptosis in human osteosarcoma cells. Cancer Res 59: 2190-2194, 1999.